PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this RESPONSE and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Ariel Fletcher — 11/18/2004

Ariel Fletcher — Date of Deposit

Applicant: Yu	Group: 1632
Serial No.: 09/935,386	Confirmation No.: 1866
Filed: August 22, 2001	Examiner: T. N. Ton
For: *IN VIVO* ANIMAL MODEL OF HUMAN LEUKEMIA	Our Ref.TSRI 753.1

OK to enter
3.1.05
TNT

RESPONSE AND AMENDMENT

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Response and Amendment is being filed in response to the Office Action mailed on September 20, 2004 issued in association with the above-captioned application. Enclosed is a Notice of Appeal and a check in the amount of $340.00. Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 4 of this paper.

This listing of claims will replace all prior versions, and listings, of claims in the application:

OK to enter
3.1.05
TNT

Listing of Claims:

1. (Currently amended) A process for making an *in vivo* model of human leukemia comprising

a) pre-conditioning an immunodeficient mouse by administering to the mouse a sub-lethal dose of irradiation and injecting the mouse with an effective pre-conditioning amount of mononuclear cells derived from human fetal cord blood;

b) maintaining the mouse from step (a) for 5 to 10 days; ~~and~~

c) injecting the mouse from step (b) with an effective engrafting amount of primary human leukemia cells; and

d) allowing the primary human leukemia cells to engraft in the mouse to produce the *in vivo* model of human leukemia.

2. (Canceled)

3. (Previously presented) The process of claim 1 wherein the immunodeficient mouse is a NOD/scid mouse.

4. (Previously presented) The process of claim 1 wherein administering the sub-lethal dose of irradiation is accomplished by irradiating the mouse with 300 to 400 rads of total body gamma radiation.

5. (Previously presented) The process of claim 1 wherein the effective engrafting amount of primary human leukemia cells is from 10^6 to 10^7 cells.

6. (Original) The process of claim 1 wherein the primary human leukemia cells are T-cell acute lymphoblastic leukemia (T-